A
AffyImmune Therapeutics
Biopharmaceutical company developing genetically engineered immune cells to fight cancer
About AffyImmune Therapeutics
AffyImmune Therapeutics is a biotechnology company focused on advancing cancer immunotherapy by developing proprietary CAR T cell therapies specifically designed to target and destroy solid tumors. The company operates in the oncology market, serving patients with various types of solid tumors. Its business model revolves around the research, development, and commercialization of these advanced therapies. AffyImmune generates revenue through partnerships, licensing agreements, and potentially through direct sales of its therapies upon regulatory approval. The company’s core technology fine-tunes the affinity of CAR T cells to selectively kill tumor cells while sparing healthy cells, thereby reducing toxicity and enhancing the efficacy and longevity of the treatment. Additionally, their engineered CAR T cells can be monitored in real-time during patient treatment, providing valuable data on distribution and activity. AffyImmune's leadership team brings extensive experience in biotechnology and drug development, driven by a commitment to creating life-saving, patient-centric treatments.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2021 | $10M | $40M | ORI Capital | — |
| EARLY VCEquity / VC | Aug 2018 | $1M | $4M | Undisclosed | — |
Growth signals
Latest recorded traffic for AffyImmune Therapeutics is 690 monthly website visits, down 42.5% over the last three months. AffyImmune Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AffyImmune Therapeutics in the Natick ecosystem
The AffyImmune Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
ORI Capital
Other known investors2 additional known investors
Cornell Tech
Cornell University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AffyImmune Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AffyImmune Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










